Advertisement

Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review

Published:October 09, 2019DOI:https://doi.org/10.1016/j.ygyno.2019.06.017

      Highlights

      • Women at risk for hereditary gynecologic cancers have unique concerns regarding fertility and hormonal health.
      • There are multiple fertility preservation strategies that can be used to help women achieve their procreative goals.
      • Genetic testing can be used before embryo transfer to identify whether an embryo carries a pathogenic gene variant.
      • For women with who don’t have a personal history of breast cancer, hormone therapy can be considered.

      Abstract

      Providers who care for women at risk for hereditary gynecologic cancers must consider the impact of these conditions on reproductive and hormonal health. This document reviews potential options for cancer prevention, family building, genetic testing and management of surgical menopause in this patient population.
      Capsule: Women predisposed to hereditary gynecologic cancer have options for fertility preservation, preimplantation genetic testing to select embryos without pathogenic variants, pregnancy through gestational carriers after hysterectomy and hormone replacement.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Obstet. Gynecol. 2017; 130: e110-e126
        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • Risch H.A.
        • Eyfjord J.E.
        • Hopper J.L.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am. J. Hum. Genet. 2003; 72: 1117-1130
        • Satagopan J.M.
        • Boyd J.
        • Kauff N.D.
        • Robson M.
        • Scheuer L.
        • Narod S.
        • Offit K.
        Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
        Clin. Cancer Res. 2002; 8: 3776-3781
        • Practice Bulletin No 147
        Lynch Syndrome. Obstet Gynecol. 2014; 124: 1042-1054
        • Bonadona V.
        Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
        JAMA. 2011; 305: 2304-2310
        • Rosenthal A.N.
        • Fraser L.S.M.
        • Philpott S.
        • Manchanda R.
        • Burnell M.
        • et al.
        Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
        J Cin Oncol. 2017; 35: 1411-1420
        • Havrilesky L.J.
        • Moorman P.G.
        • Lowery W.J.
        • et al.
        Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.
        Obstet. Gynecol. 2013; 122: 139-147
        • Iodice S.
        • Barile M.
        • Rotmensz N.
        • et al.
        Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
        Eur. J. Cancer. 2010; 46: 2275-2284
        • Gierisch J.M.
        • Coeytaux R.R.
        • Peragallo U.R.
        • et al.
        Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.
        Cancer Epidemiol. Biomark. Prev. 2013; 22: 1931-1943
        • Mørch L.S.
        • Hannaford P.C.
        • Lidegaard Ø.
        Contemporary hormonal contraception and the risk of breast Cancer.
        N. Engl. J. Med. 2018; 378: 1265-1266
        • Walker J.L.
        • Powell C.B.
        • Chen L.M.
        • Carter J.
        • Bae Jump V.L.
        • Parker L.P.
        • Borowsky M.E.
        • Gibb R.K.
        Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.
        Cancer. 2015; 121 (Jul 1): 2108-2120
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA. 2010; 304: 967-975
        • Domchek S.M.
        • Friebel T.M.
        • Neuhausen S.L.
        • et al.
        Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
        Lancet Oncol. 2006; 7: 223-229
        • Finch A.P.
        • Lubinski J.
        • Møller P.
        • Singer C.F.
        • Karlan B.
        • Senter L.
        • Rosen B.
        • Maehle L.
        • Ghadirian P.
        • Cybulski C.
        • Huzarski T.
        • Eisen A.
        • Foulkes W.D.
        • Kim-Sing C.
        • Ainsworth P.
        • Tung N.
        • Lynch H.T.
        • Neuhausen S.
        • Metcalfe K.A.
        • Thompson I.
        • Murphy J.
        • Sun P.
        • Narod S.A.
        Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
        J. Clin. Oncol. 2014; 32 (May 20): 1547-1553
        • Powell C.B.
        • Kenley E.
        • Chen L.M.
        • Crawford B.
        • McLennan J.
        • Zaloudek C.
        • Komaromy M.
        • Beattie M.
        • Ziegler J.
        Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
        J. Clin. Oncol. 2005; 23: 127-132
        • Callahan M.J.
        • Crum C.P.
        • Medeiros F.
        • Kindelberger D.W.
        • Elvin J.A.
        • Garber J.E.
        • Feltmate C.M.
        • Berkowitz R.S.
        • Muto M.G.
        Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
        J. Clin. Oncol. 2007; 25: 3985-3990
      2. Birrer N, Chinchilla C, Del Carmen M, Dizon DS. Is Hormone replacement therapy safe in women with a BRCA mutation? A systematic review of the contemporary literature. Am. J. Clin. Oncol. 2016 (Feb 2. [Epub ahead of print).

        • Lavie O.
        • Hornreich G.
        • Ben-Arie A.
        • Rennert G.
        • Cohen Y.
        • Keidar R.
        • Sagi S.
        • Lahad E.L.
        • Auslander R.
        • Beller U.
        BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
        Gynecol. Oncol. 2004; 92: 521-524
      3. . Shu CA1, Pike MC2, Jotwani AR3, Friebel TM4, Soslow RA5, Levine DA6, Nathanson KL7, Konner JA8, Arnold AG3, Bogomolniy F6, Dao F6,. Uterine cancer after risk-reducing Salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016 Nov 1; 2(11): 1434–1440. doi:https://doi.org/10.1001/jamaoncol.2016.1820.

        • Weiss N.S.
        • Sayvetz T.A.
        Incidence of endometrial cancer in relation to the use of oral contraceptives.
        N. Engl. J. Med. 1980; 302: 551-554
        • Lu K.H.
        • Loose D.S.
        • Yates M.S.
        • Nogueras-Gonzalez G.M.
        • Munsell M.F.
        • Chen L.M.
        • Lynch H.
        • Cornelison T.
        • Boyd-Rogers S.
        • Rubin M.
        • Daniels M.S.
        • Conrad P.
        • Milbourne A.
        • Gershenson D.M.
        • Broaddus R.R.
        Prospective, multi-center randomized intermediate biomarker study of Oral contraceptive vs. Depo-Provera for prevention of endometrial cancer in women with Lynch syndrome.
        Cancer Prev. Res. (Phila.). 2013 Aug; 6 (Published online 2013 May 2) (PMCID: PMC3737517): 774-781
        • Jareid M.
        • JC Thalabard M. Aarflot
        • Bovelstad H.M.
        • Lund E.
        • Braaten T.
        Levonorgestrel-releasing intrauterine system use is associated with decrease risk of ovarian and endometrial cancer without increased risk of breast cancer. Results from the NOWAC study.
        Gynecol. Oncol. 2018; 149: 127-132
        • Pal N.
        • Broaddus R.R.
        • Urbauer D.L.
        • Balakrishnan N.
        • Milbourne A.
        • Schmeler K.M.
        • et al.
        Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the Levonorgetrel-releasing intrauterine device.
        Obstet. Gynecol. 2018; 131: 109-116
        • Schmeler K.M.
        • Lynch H.T.
        • Chen L.M.
        • et al.
        Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
        N. Engl. J. Med. 2006; 354: 261-269
        • Kim J.
        • Skrzynia C.
        • Mersereau J.E.
        A pilot study of BRCA mutation carriers’ knowledge about the clinical impact of prophylactic oophorectomy and views on fertility consultation: a single–center pilot study.
        J Genet Counsel. 2015; 24: 149-157
      4. Chan JL, Johnson LNC, Sammel MD, DiGiovanni L, Voong C, Domchek SM, et al. Reproductive decision–making in women with BRCA1/2 mutations. J Genet Counsel. (ePub ahead of print).

        • Steiner A.Z.
        • Pritchard D.
        • Stanczyk F.Z.
        • Kesner J.S.
        • Meadows J.W.
        • Herring A.H.
        • Baird D.D.
        Association between biomarkers of ovarian reserve an infertility among older women of reproductive age.
        JAMA. 2017; 318: 1367-1376
        • Lin W.T.
        • Beattie M.
        • Chen L.M.
        • Oktay K.
        • Crawford S.L.
        • Gold E.B.
        • Cedars M.
        • Rosen M.
        Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.
        Cancer. 2013; 119: 1652-1659
        • Collins I.M.
        • Milne R.L.
        • McLachlan S.A.
        • Friedlander M.
        • Hickey M.
        • Weideman P.C.
        • et al.
        Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
        J. Clin. Oncol. 2013; 31: 3920-3925
        • Rzepka-Gorska
        • Tarnowski B.
        • Chudecka-Glaz A.
        • Gorski B.
        • Zielinska D.
        • Toloczko-Grabarek A.
        Premature menopause in patients with BRCA1 gene mutation.
        Breast Cancer Res. Treat. 2006; 100: 59-63
        • Oktay K1.
        • Kim J.Y.
        • Barad D.
        • Babayev S.N.
        Ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian Cancer risks.
        JCO. 2010; 28: 240-244
        • Wang E.T.
        • Pisarska M.D.
        • Bresee C.
        • Chen Y.D.
        • Lester Y.
        • Afshar Y.
        • et al.
        BRCA1 germline mutations may be associated with reduced ovarian reserve.
        Fertil. Steril. 2014; 102: 1723-1728
        • Giordano S.
        • Garrett–Mayer E.
        • Mittal N.
        • Smith K.
        • Passaglia Shulman L.
        • Gradishar W.
        • et al.
        Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast/ovarian Cancer risk.
        J Adolescent and Young Adult Oncology. 2016; 5: 337-343
        • Michaelson-Cohen R.
        • Mor P.
        • Srebnik N.
        • Beller U.
        • Levy-Lahad E.
        • Eldar-Geva T.
        BRCA mutation carriers do not have compromised ovarian reserve.
        Int. J. Gynecol. Cancer. 2014; 24: 233-237
        • Shapira M.
        • Raanani H.
        • Feldman B.
        • et al.
        BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
        Fertil. Steril. 2015; 104: 1162-1167
        • Moslehi R.
        • Singh R.
        • Lessner L.
        • Friedman J.M.
        Impact of BRCA mutations on female fertility and offspring sex ratio.
        Am. J. Hum. Biol. 2010; 22: 201-205
        • Pal T.
        • Keefe D.
        • Sun P.
        • Narod S.A.
        Fertility in women with BRCA mutations: a case-control study.
        Fertil. Steril. 2010; 93: 1805-1808
        • Kwiatkowski F.
        • Arbre M.
        • Bidet Y.
        • Laquet C.
        • Uhrhammer N.
        • Bignon Y.J.
        BRCA mutations increase fertility in families at hereditary breast/ovarian cancer risk.
        PLoS One. 2015; 10e0127363
        • Phillips K.A.
        • Collins I.M.
        • Milne R.L.
        • McLachlan S.A.
        • Friedlander M.
        • Hickey M.
        • Stern C.
        • Hopper J.L.
        • Fisher R.
        • Kannemeyer G.
        • et al.
        Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
        Hum. Reprod. 2016; 31: 1126-1132
        • Practice Committees of American Society for Reproductive Medicine
        Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline.
        Fertil. Steril. 2013 Jan; 99 (Epub 2012 Oct 22.): 37-43https://doi.org/10.1016/j.fertnstert.2013.09.028
        • Practice Committee of the American Society for Reproductive Medicine
        Fertility drugs and cancer: a guideline.
        Fertil. Steril. 2016; 106: 1617-1625
        • Kim J.
        • Turan V.
        • Oktay K.
        Long-term safety of Letrozole and gonadotropin stimulation for fertility preservation in women with breast Cancer.
        Clin. Endocrinol. Metab. 2016; 101: 1364-1371
        • Perri T.
        • Lifshitz D.
        • Sadetzki S.
        • Oberman B.
        • Meirow D.
        • Ben-Baruch G.
        • Friedman E.
        • Korach J.
        Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
        Fertil. Steril. 2015; 103 (May): 1305-1312
        • Gronwald J.
        • Glass K.
        • Rosen B.
        • Karlan B.
        • Tung N.
        • Neuhausen S.L.
        • Moller P.
        • Ainsworth P.
        • Sun P.
        • Narod S.A.
        • Lubinski J.
        • Kotsopoulos J.
        Hereditary Breast Cancer Clinical Study Group. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
        Fertil. Steril. 2016; 105 (Mar): 781-785
        • Testa G.
        • McKenna G.J.
        • Gunby R.T.
        • Anthony T.
        • Koon E.C.
        • Warren A.M.
        • Putman J.M.
        • Zhang L.
        • de Prisco Mitchell J.M.
        • Wallis K.
        • Kintmalm G.B.
        • Olausson M.
        • Johannesson L.
        First live birth after uterus transplantation in the United States.
        Am. J. Transplant. 2018; 18: 1270-1274
      5. Practice Committee of Society for Assisted Reproductive Technology; Practice Committee of American Society for Reproductive Medicine. Preimplantation genetic testing: a practice committee opinion. Fertil. Steril. 2008; 90: S136–43.

        • IA Derks–Smeets
        • de Die-Smulders C.E.
        • Mackens S.
        • et al.
        Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.
        Breast Cancer Res. Treat. 2014; 145: 673-681
        • Julian-Reynier C.
        • Fabre R.
        • Coupier I.
        • Stoppa-Lyonnet D.
        • Lasset C.
        • Caron O.
        • Mouret-Fourme E.
        • Berthet P.
        • Faivre L.
        • Frenay M.
        • Gesta P.
        • Gladieff L.
        • Bouhnik A.D.
        • Protière C.
        • Noguès C.
        BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis.
        Genet Med. 2012; 14 (May): 527-534
        • Staton A.D.
        • Kurian A.W.
        • Cobb K.
        • Mills M.A.
        • Ford J.M.
        Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
        Familial Cancer. 2008; 7: 179-186
        • Menon U.
        • Harper J.
        • Sharma A.
        • Fraser L.
        • Burnell M.
        • ElMasry K.
        • Rodeck C.
        • Jacobs I.
        Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer.
        Hum. Reprod. 2007; 22 (Jun): 1573-1577
        • Brezina P.R.
        • Kearns W.G.
        The evolving role of genetics in reproductive medicine.
        Obstet. Gynecol. Clin. N. Am. 2014; 41: 41-55
      6. Practice bulletin no. 163 summary: screening for fetal aneuploidy.
        Obstet. Gynecol. 2016 May; 127 (MID: 27101120): 979-981https://doi.org/10.1097/AOG.0000000000001439
        • Marchetti C.
        • Iadarola R.
        • Palaia I.
        • di Donato V.
        • Perniola G.
        • Muzii L.
        • Panici P.B.
        Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
        Menopause. 2014; 21: 763-768
        • Chapman J.S.
        • Powell C.B.
        • McLennan J.
        • Crawford B.
        • Mak J.
        • Stewart N.
        • Chen L.M.
        Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
        Gynecol. Oncol. 2011; 122: 339-343
        • Finch A.
        • Metcalfe K.A.
        • Chiang J.K.
        • Elit L.
        • McLaughlin J.
        • Springate C.
        • Demsky R.
        • Murphy J.
        • Rosen B.
        • Narod S.A.
        The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
        Gynecol. Oncol. 2011; 121: 163-168
        • Finch A.
        • Evans G.
        • Narod S.A.
        BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
        Womens Health (Lond). 2012; 8: 543-555
        • Birrer
        Collaborative group on hormonal factors in breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.
        Lancet. 1997; 1997: 1047-1059
        • Parker W.H.
        • Broder M.S.
        • Chang E.
        • Feskanich D.
        • Farquhar C.
        • Liu Z.
        • Shoupe D.
        • Berek J.S.
        • Hankinson S.
        • Manson J.E.
        Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study.
        Obstet. Gynecol. 2009; 113: 1027-1037
        • Jacoby V.L.
        • Grady D.
        • Wactawski-Wende J.
        • Manson J.E.
        • Allison M.A.
        • Kuppermann M.
        • Sarto G.E.
        • Robbins J.
        • Phillips L.
        • Martin L.W.
        • O’Sullivan M.J.
        • Jackson R.
        • Rodabough R.J.
        • Stefanick M.L.
        Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women’s Health Initiative observational study.
        Arch. Intern. Med. 2011; 171: 760-768

      Linked Article